A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
Status:
Completed
Trial end date:
2016-08-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5
mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by
randomized, double-blind, placebo-controlled, parallel-group comparison in order to determine
the clinical dose of TAK-272.